title: PARP inhibitors: current status and implications for anticancer therapeutics.
abstract: Poly(ADP-ribose) polymerases (PARPs) comprise of a large family of 17 proteins encoded by various genes which participate in genome maintenance, apoptosis, inflammatory responses and the regulation of gene expression programs. PARP inhibitors, as therapeutic agents, come into play acting on both PARP 1 and PARP 2. These drugs seem to target tumor cells in a moment of vulnerability when they are undergoing DNA repair. In the past few years this class of anti-cancer drug has been discovered to show a promising niche in the clinic.
authors.affiliation: Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. asfandyarsheikh@gmail.com.
authors.forename: Hadi
authors.initials: H
authors.lastname: Usmani
authors.forename: Syed Ather
authors.initials: SA
authors.lastname: Hussain
authors.forename: Asfandyar
authors.initials: A
authors.lastname: Sheikh